1Z2MAP1O
1Z2MAP1O, also known as 1--2-propan-1-one, is a monoamine releasing agent and serotonin receptor modulator of the indolizinylethylamine family. It is an analogue of BK-NM-AMT in which the indole ring has been replaced with an indolizine ring.
1Z2MAP1O has been found to be a serotonin and dopamine releasing agent as well as a weak serotonin 5-HT1B receptor agonist and serotonin 5-HT2B receptor antagonist. Conversely, its activity as a norepinephrine releasing agent was not reported, and it was inactive at the remaining sites of the 47screened targets. The drug's values for induction of monoamine release were 109nM for serotonin and 227nM for dopamine in Chinese hamster ovary cells expressing the human monoamine transporters. The dopamine/serotonin ratio was 0.48. Its at the serotonin 5-HT1B receptor was 1,130nM, whereas its values were 2,140nM at the serotonin 5-HT2B receptor, 2,410nM at the dopamine transporter, and 5,690nM at the norepinephrine transporter. 1Z2MAP1O's inhibition of the serotonin transporter was not reported.
1Z2MAP1O was patented by Matthew Baggott of Tactogen in 2023.